Sugi Predict

Sugi Predict / Compounds / SCHEMBL4307722

SCHEMBL4307722

SCHEMBL4307722

CC(C)(O)c1cccc(-n2nc(-c3ccccc3)cc2NC(=O)Nc2cccc3ccccc23)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK14 Q16539 16/20 0.63
▸ MAPK13 O15264 2/20 0.63
▸ MAPK12 P53778 2/20 0.63
▸ MAPK11 Q15759 2/20 0.63
▸ NTRK1 P04629 1/20 0.61
▸ DDR2 Q16832 3/20 0.58
▸ MAPK9 P45984 3/20 0.58
▸ SRC P12931 1/20 0.58
▸ DYRK3 O43781 1/20 0.51
▸ RPS6KB1 P23443 1/20 0.51
▸ MARK3 P27448 1/20 0.51
▸ FRK P42685 1/20 0.51
▸ GSK3B P49841 1/20 0.51
▸ MAP4K2 Q12851 1/20 0.51
▸ STK3 Q13188 1/20 0.51
▸ LMNA P02545 2/20 0.51
▸ CDK8 P49336 6/20 0.51
▸ RET P07949 3/20 0.51
▸ PDGFRA P16234 2/20 0.51
▸ MAP4K5 Q9Y4K4 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4298989 0.87 NTRK1 (0.77) MAPK14MAPK13MAPK12MAPK11NTRK1
SCHEMBL3294133 0.87 MAPK14 (0.81) MAPK14MAPK13MAPK12MAPK11NTRK1
SCHEMBL4048212 0.86 MAPK14 (0.62) MAPK14MAPK13MAPK12MAPK11NTRK1
SCHEMBL13576983 0.85 MAPK14 (0.69) MAPK14MAPK13MAPK12MAPK11NTRK1
SCHEMBL16317146 0.83 MAPK14 (0.58) MAPK14MAPK13MAPK12MAPK11NTRK1
SCHEMBL4052780 0.80 NTRK1 (0.60) MAPK14MAPK13MAPK12MAPK11NTRK1
SCHEMBL3300816 0.79 MAPK14 (0.78) MAPK14MAPK13MAPK12MAPK11DDR2
SCHEMBL3295817 0.79 MAPK14 (0.85) MAPK14MAPK13MAPK12MAPK11NTRK1
SCHEMBL16585636 0.76 NTRK1 (1.00) MAPK14MAPK13MAPK12MAPK11NTRK1
SCHEMBL3297362 0.75 MAPK14 (0.85) MAPK14MAPK13MAPK12MAPK11NTRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090312349-A1 ANTI-INFLAMMATORY MEDICAMENTS DECIPHERA PHARMACEUTICALS, LLC 2009-12-17 — — US disclosed
US-20090312349-A1 ANTI-INFLAMMATORY MEDICAMENTS DECIPHERA PHARMACEUTICALS, LLC 2009-12-17 — — US disclosed
US-20090312349-A1 ANTI-INFLAMMATORY MEDICAMENTS DECIPHERA PHARMACEUTICALS, LLC 2009-12-17 — — US disclosed
US-20070191336-A1 p38 kinase inhibitors DECIPHERA PHARMACEUTICALS, LLC 2007-08-16 — — US disclosed
US-20070191336-A1 p38 kinase inhibitors DECIPHERA PHARMACEUTICALS, LLC 2007-08-16 — — US disclosed
US-20070191336-A1 p38 kinase inhibitors DECIPHERA PHARMACEUTICALS, LLC 2007-08-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312349-A1 ANTI-INFLAMMATORY MEDICAMENTS ABL2, ABL1, PTK2 MAPK14 80/4885MAPK13 183/4885MAPK12 118/4885
US-20070191336-A1 p38 kinase inhibitors MAPK1, MAP3K8, MAP3K1 MAPK14 29/4885MAPK13 41/4885MAPK12 37/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.